PRICE PER COPY ₹25/- LICENSED TO POST WITHOUT PREPAYMENT LICENCE NO. MR/Tech/WPP-337/West/2018 RNI REGN. NO. 18921/1970 REGN NO. MCW/95/2018-20

## IDMA BULLETIN

VOL. NO. 49

ISSUE NO. 15 (PAGES: 44)

15 TO 21 APRIL 2018

ISSN 0970-6054

**WEEKLY PUBLICATION** 

## Troikaa wins 'India Pharma Innovation of the Year Award'

Recently, Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals, conferred *India Pharma Innovation of the Year Award* to Troikaa Pharmaceuticals Ltd. The award was given in recognition to company's achievement towards patented innovation in the field of Novel Drugs Delivery Systems.



On behalf of Troikaa Pharma, the Award was received by Dr Ketan R Patel, CMD by the hands of Shri Ananth Kumar, Hon'ble Minister (Chemicals & Fertilizers), Government of India during the Inaugural Session of India Pharma Exhibition 2018, held in Bengaluru on 15<sup>th</sup> February 2018.

Troikaa Pharmaceutical Ltd is a global pharmaceutical company engaged *inter alia* in Research and Development, Production, Marketing, Sales and Export of proprietary pharmaceuticals formulations. Working on the concept of '*Imagine-Innovate*', the Company's strength lies in its ability to introduce innovative products in the market. Company is headed by Dr Ketan R Patel, who is an innovator, entrepreneur and pharmacist.

In past, Troikaa's path breaking innovation *Dynapar QPS* (Diclofenac Diethylamine and Absolute Alcohol Non-Aqueous Topical Solution) was conferred National Award by Department of Science & Technology, Government of India. *Dynapar QPS* is the First of its kind topical solution of Diclofenac protected by patent applications in 100 countries.

The earlier innovation of the company, *Dynapar AQ* (Diclofenac Injection 75mg / 1 ml) has also won National Award from Department of Scientific and Industrial Research, Goovernment of India. *Dynapar AQ* is world's first painless injection which is patented in 99 countries. Company's research wing always aims to provide cost-effective and innovative treatment options to address society's medical needs.

Source: Troikaa Press Release, 01.03.2018